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Blodtrykk, fedme, og jern- og feittinnhald i serum som 
risikofaktorar for iskjemisk hjartesjukdom 
Det er gjort mange studiar på risikofaktorar for iskjemisk hjartesjukdom der blodtrykk, 
fedme, jern og lipidar har vist seg å spele ei rolle. Det er fleire som dør av 
hjartesjukdom relatert til høgt blodtrykk i eldre aldersgrupper, men den relative risikoen 
har vist seg å vere høgare hjå yngre. Det er uklart korleis fedme innverkar på samspelet 
mellom blodtrykk og død av hjartesjukdom; nokon meiner tynne har større risiko, 
medan andre meiner dei tjukke er mest utsette. Jern si rolle er også uklar; nokon meiner 
det er større risiko med for mykje, andre med for lite. Vidare er det mange ulike måtar å 
måle blodtrykk, fedme og lipidar på. Dei som har vist seg å gje mest informasjon i 
forhold til risiko for død av hjartesjukdom er gjennomsnittet av systolisk og diastolisk 
blodtrykk, forholdstalet mellom midje- og hoftemål justert for kroppsmasseindeks, og 
forholdstalet mellom total- og HDL-kolesterol. 
 Gjennom kopling av data frå Helseundersøkelsen i Nord-Trøndelag og 
Dødsårsaksregisteret har vi undersøkt samanhengen mellom blodtrykk og 
hjartesjukdom, og korleis alder og kroppsmasseindeks spelar inn på denne 
samanhengen. Vidare har vi undersøkt samanhengen mellom jernstatus i blod og risiko 
for død av hjartesjukdom, og korleis oppfølgingstida spelar inn på denne samanhengen. 
Vi har også undersøkt ulike indeksar av blodtrykk, fedme og lipidar for å finne ut kva 
indeks som gjev mest informasjon i forhold til risikoen for død av hjartesjukdom. 
 Vi fann at samanhengen mellom blodtrykk og død av hjartesjukdom var mykje 
sterkare hjå dei under 65 år enn dei over. Denne samanhengen var også sterkare blant 
dei tynne enn blant overvektige og tjukke. Vidare fann vi at lågt jerninnhald i blodet var 
relatert til auka risiko for død av hjartesjukdom, og at denne risikoen var sterkast tidleg i 
oppfølgingstida. Vi fann også at systolisk blodtrykk hjå menn og pulstrykk hjå kvinner, 
forholdstalet mellom midje- og hoftemål justert for kroppsmasseindeks hjå menn og 
kvinner, og forholdstalet mellom total- og HDL-kolesterol hjå menn og kvinner gav 
mest informasjon i forhold til risiko for død av hjartesjukdom. 
Kandidat: Bjørn Mørkedal
Institutt: Institutt for samfunnsmedisin
Veiledere: Lars Vatten og Pål Romundstad
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71 Introduction 
1.1 Blood pressure and ischaemic heart disease mortality 
The first recorded attempt of measuring blood pressure in western science was done 
invasively in a horse by Stephen Hales in 1711 (1). However, the first non-invasive 
method of measuring blood pressure in humans is credited to Samuel Siegfried Karl 
Ritter von Basch who invented the sphygmomanometer in 1881 (2). Nikolai 
Sergeyevich Korotkov further improved the technique by measuring blood pressure in 
the brachial artery in 1905, using a stethoscope and noting tapping sounds as the cuff 
deflated (2). The first, large epidemiological study to evaluate the increased risk of 
mortality among those with high blood pressure was the Build and Blood Pressure 
Study in 1959 (3), with the emphasis on the importance of systolic blood pressure (4). 
 Over the last century, there has been much debate over which index of blood 
pressure is most useful. Whereas diastolic blood pressure was found to be best in most 
clinical trials and widely used as the best predictor of later disease, most observational 
studies found systolic blood pressure to be more informative (5). The emphasis shifted 
from diastolic blood pressure to systolic blood pressure around 1993 with the new 
classification described in the JNC-V report (6). Based on the largest meta-analysis thus 
far, the Prospective Studies Collaboration reported in 2002 that mid blood pressure (the 
average of systolic and diastolic blood pressure) is the most informative in relation to 
ischaemic heart disease mortality (7), followed by mean arterial pressure, systolic blood 
pressure, diastolic blood pressure and pulse pressure. 
 In addition to the different indices, the method of measuring blood pressure is 
also relevant. The office measurement should be standardized (8,9), and Ambulatory 
8Blood Pressure Monitoring or self-measurement should be considered if white coat 
hypertension is suspected (8,9). Furthermore, the apparatus itself, whether auscultatory 
or oscillometric, may also make a difference (10).
It has been suggested that the risk of ischaemic heart disease mortality starts to 
increase at around 140 mmHg (11). The Prospective Studies Collaboration have refuted 
this, however, stating that the risk of ischaemic heart disease mortality does not have a 
cut-off value, but shows a linear increase from about 115/75 mmHg (7). Still, the 
clinical treatment of hypertension does follow different cut-off values of blood pressure, 
with additional consideration of other risk factors or organ disease (9), which may often 
be prevalent in many individuals with high blood pressure (12). 
 Although the absolute rates of cardiovascular mortality are higher at old age, the 
proportional rates have been found to be stronger in middle age in both the western (7)
and eastern (13) hemispheres. The reason for the association with age is not yet 
understood. 
  
1.2 Obesity and ischaemic heart disease mortality 
Obesity as a health problem has been recognized since the Hindu physician Sushruta 
discovered the sweet, diabetic urine in the obese around 600 BC (14). However, the 
medical awareness of obesity as a health problem was not fully realized until the 
Metropolitan Life Insurance Company published the results of a study from 1911-1935 
(15), where obesity was objectively linked to excess mortality. Today, obesity is 
increasingly prevalent in both children and adults (16), with implications for 
cardiovascular health (17,18). 
9 The concept of “ideal weight” was introduced during the turn of the 20th century 
(19), using a percentage of the average weight of persons of the same height. The 
Metropolitan Life Insurance Company introduced tables of height and weight in 1959 
that became widely used (20). The body-mass index was described already in 1832 by 
Adolphe Quetelet (21), but was not widely used until 1972 (22). It has been the most 
used index of general adiposity since then, but the use of waist-to-hip ratio or waist 
circumference as a measure of abdominal adiposity has later been shown to be a better 
predictor of mortality when used together with body-mass index (23). 
 The association of body-mass index with all-cause mortality displays a “U-
shaped” curve, with higher mortality at both ends of the distribution of body-mass index 
(24). Specifically, the curve for ischaemic heart disease mortality has a “J-shaped” 
form, with stronger associations at higher levels of body-mass index (24). However, the 
association of abdominal adiposity adjusted for body-mass index with mortality from 
ischaemic heart disease, appears to display a linear curve (23). The choice of whether to 
use waist-to-hip ratio or waist circumference as a measure of abdominal adiposity, 
adjusted for body-mass index, is still under debate. The waist-to-hip ratio benefits from 
having less potential of collinearity with body-mass index than waist circumference, 
while waist circumference is easier to measure (23).
There is an established positive association between obesity and blood pressure 
(25). It has also been shown that weight gain increases blood pressure (26) and that 
losing weight reduces blood pressure (27). However, the role of body-mass index as an 
effect modifier in the association of blood pressure with ischaemic heart disease 
mortality is unresolved. Some investigators have found that body mass index may be an 
effect modifier (28-34), but others have not confirmed this (35-39).  
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1.3 Iron status and ischaemic heart disease mortality 
The health properties of iron have been known since the ancient Greeks administered 
iron against fatigue among soldiers, a treatment that was probably given due to blood 
loss and anaemia sustained at the battlefield (40). The haemoglobin protein was 
discovered in 1840 by Friedrich Ludwig Hünefeld (41), and its function in the blood 
was recognized by Sir George Gabriel Stokes in 1863 (42). In 1937, Vilém Laufberger 
discovered the ferritin protein (43). Transferrin was discovered later; when Arthur
Schade and Leona Caroline described transferrin and its saturation with iron in human 
plasma in 1946 (44).  
 Thus, iron exists in many forms in the human body. Ferritin is the storage 
protein (45), and transferrin is the transport protein with two seats for free serum iron. 
The percentage of occupied transferrin seats to all seats is called transferrin saturation 
(45). Total iron-binding capacity is the number of seats for serum iron in total, or 
equivalent to two times transferrin. The transferrin receptor modulates iron release from 
transferrin (45). Haemoglobin consists of haem with iron and globin (46), and is 
therefore an important component of red blood cells. 
 In 1981, Jerome Sullivan hypothesized that the reason for increased risk of heart 
disease in men and post-menopausal women, compared to premenopausal women, was 
increased stores of iron in the blood (47). This suggestion has been supported by some 
studies on the association of transferrin saturation (48-53), serum iron (54), total iron 
binding capacity (52,55), and ferritin (56-60) with rates of cardiovascular disease. 
Opposite findings, showing that low levels of iron in the blood may be associated with 
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increased risk of cardiovascular disease, have also been reported for transferrin 
saturation (61), serum iron (50,53,62), and ferritin (52). 
It is unclear why the associations of iron status with cardiovascular disease have 
differed so much between studies, but regression dilution and confounding by chronic 
or inflammatory diseases have been suggested to explain the discrepant findings (63). 
1.4 Serum lipids and IHD mortality 
The first discovery of a fat transport system in humans is credited to Robert Boyle in 
1665 (64). Later, cholesterol was found in human blood by Felix Boudet in 1833 (65). 
During World War II, a research group from Harvard University studied human plasma 
intended for treating wounded soldiers and subsequently isolated low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, among other 
lipoproteins (66). 
The positive association of triglycerides with cardiovascular disease was found 
in 1959 (67), and for total cholesterol in 1961 (68). From the Framingham study, the 
positive association of LDL cholesterol with cardiovascular disease (69), and the 
negative association of HDL cholesterol (70), were reported in 1966 and 1977, 
respectively. These results have remained consistent in later studies (71). 
The most informative serum lipid index in relation to ischaemic heart disease 
mortality may be the ratio of total:HDL cholesterol, followed by non-HDL cholesterol, 
and total cholesterol (71). It appears that the use of apolipoproteins may be equivalent to 
using conventional lipid measurements in relation to coronary heart disease risk; thus, 
Apo B has a similar risk profile as non-HDL cholesterol and Apo A1 is similar to that of 
12
HDL cholesterol (72). However, based on the results of a case-control study, the ratio of 
Apo B/Apo A1 may be more informative than the total:HDL cholesterol ratio in relation 
to myocardial infarction morbidity (73). 
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2 Objective 
Our objective was to study associations of different risk factors with ischaemic heart 
disease mortality, and to assess potential effect modification by relevant factors.  We 
also wanted to assess informativeness of different indices of known cardiovascular risk 
factors. More specifically, our aims were:
I To study the association of blood pressure with ischaemic heart disease 
mortality, and to assess potential effect modification by age and/or body-mass 
index. 
II To study the association of iron status with ischaemic heart disease mortality, 
and to assess whether associations of iron status may vary according to follow-
up time.
III  To study the informativeness of different indices of blood pressure, obesity and 
serum lipids in relation to ischaemic heart disease mortality
14
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3 Materials and methods 
3.1 The Nord-Trøndelag Health Study (HUNT) 
Norway is divided into 19 administrative regions, called counties, and Nord-Trøndelag 
is one of them. It is located in the central part of Norway, and is considered fairly 
representative for the Norwegian population. The first Nord-Trøndelag Health Study 
(HUNT 1) was conducted from January 1984 to February 1986. The second Nord-
Trøndelag Health Study (HUNT 2) was conducted from August 1995 to June 1997. The 
population was approximately 127 000 in both 1984-86 and 1995-97 (74). The 
population of Nord-Trøndelag is stable, with a net migration out of the county of 0.1 %
per year (1984-2010). It is also homogenous, with less than 3 % non-Caucasians at the 
time of HUNT 2 (75). Paper I in this thesis uses data from HUNT 1, whereas paper II 
and III use data from HUNT 2. 
All inhabitants in Nord-Trøndelag aged 20 years or older were invited to 
participate in both HUNT 1 and HUNT 2. A total of 85 100 individuals were eligible to 
participate, and 74 977 (88.1 %) attended HUNT 1. In HUNT 2, a total of 92 936 
individuals were eligible to participate, and 66 140 (71.2 %) attended.
 In both HUNT 1 and HUNT 2, a questionnaire (questionnaire 1) was attached to 
the invitation letter (76). This questionnaire was to be completed prior to the clinical 
examination. A second questionnaire (questionnaire 2) was handed out at the clinical 
examination and should be completed and returned by mail in a pre-stamped envelope. 
Unless otherwise noted, all self-reported information that is used in this thesis comes 
from questionnaire 1. 
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 Every study participant attended a clinical examination in both HUNT 1 and 
HUNT 2, and a non-fasting venous serum sample was drawn from each participant in 
HUNT 2. More comprehensive descriptions of HUNT1 and HUNT 2 are published 
elsewhere (75,77,78). The clinical measurements, laboratory tests, and self-reported 
information that were used in the studies forming this thesis are described in section 3.3.
The mortality follow-up of the HUNT cohorts was approved by the regional 
committee for ethics in medical research, and by the Norwegian Data Inspectorate.
Participation in the HUNT study was voluntary, and each participant signed a written 
consent regarding the survey and subsequent follow-up, and to the use of data for 
research purposes. 
The HUNT studies are collaboration between the HUNT Research Centre, The 
Faculty of Medicine, NTNU, The Norwegian Institute of Public Health, Nord-
Trøndelag County Council, and the Central Norwegian Regional Health Authority. 
3.2 The Cause of Death Registry in Norway 
All deaths in Norway are reported by doctors who are required to complete a death 
certificate. Death certificates are collected by the Cause of Death Registry, for coding of 
information based on the International Classification of Diseases (ICD). Both the 
underlying and other causes of death are reported. The registry is owned by the 
Norwegian Institute of Public Health, but the data are collected and organised by 
Statistics Norway. In addition to using information from the local physicians and public 
health officers, Statistics Norway collects supplementary information from other 
sources, such as the Cancer Registry of Norway, the Medical Births Registry of 
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Norway, and autopsy reports. The unique 11-digit identification number of every 
Norwegian citizen enables linkage of data from the Cause of Death Registry with other 
data, such as data from the HUNT study. In paper I, the information on causes of death 
was complete through December 31, 2004. In paper II and paper III, it was complete 
through December 31, 2006. 
3.3 Study variables 
Information on date of death and causes of death comes from the Cause of Death 
Registry. All other information comes from the HUNT studies.
3.3.1 Blood pressure 
In HUNT 1, blood pressure was measured after two minutes rest using calibrated 
mercury manometers with standard cuff size (12x24 cm) in the sitting position (77). The 
level of the first pulse sound (phase 1) was recorded as the systolic pressure, and the 
level at which the pulse disappeared (phase 5) as diastolic pressure. Measurements were 
repeated two minutes after the first recording, and both pressures were registered with 
an accuracy of 2 mmHg. We used the average of the two measurements.  
In HUNT 2, systolic and diastolic blood pressure were measured using a 
Dinamap 845XT (Critikon) based on oscillometry, and the average of the second and 
third measurements was used.
In paper I, we divided systolic and diastolic blood pressure into seven categories 
(<119, 120-129, 130-139, 140-149, 150-159, 160-	

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and <75, 75-79, 80-84, 85-89, 90-94, 95-	
	 in 
the initial age-specific analyses. We also conducted analyses where effects were 
assessed by 20 mmHg higher systolic and by 10 mmHg higher diastolic pressure, using 
blood pressure as a continuous variable. 
In the analyses of blood pressure stratified by body-mass index, systolic and 
diastolic blood pressure were divided into the four JNC-VII (8) categories (<120, 120-
139, 140-	
	-89, 90-	

for diastolic blood pressure); these categories were chosen to avoid low numbers within 
combined categories of blood pressure and BMI.  
In paper III, we calculated mean arterial pressure as the sum of systolic blood 
pressure and twice the diastolic blood pressure divided by three. Mid blood pressure 
was calculated as the average of systolic and diastolic blood pressure. Pulse pressure 
was calculated as the difference between systolic and diastolic blood pressure. We also 
calculated and used the product of pulse pressure and mean arterial pressure. In the 
analyses of informativeness, we tested the blood pressure indices as continuous 
variables.
3.3.2 Obesity indices 
In paper I, body-mass index was calculated as body weight divided by the squared value 
of height (kg/m2), and further subdivided into three categories: <25 (lean), 25–29.9
!"#$	
&!'*In a separate analysis, we stratified body-mass index by 
four categories to investigate the possibility that low body-mass index (<18.5) could be 
attributed to prevalent but unknown disease at baseline. 
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In paper III, height was measured to the nearest centimetre, weight to the nearest 
half kilogram, and waist and hip circumferences to the nearest centimetre. From these 
indices we calculated waist-to-hip ratio, waist-to-height ratio and body-mass index.  
3.3.3 Iron status 
A non-fasting blood sample was drawn from each participant, and analysed for serum 
iron and serum transferrin concentrations, as described elsewhere (79). For the 
statistical analyses, s!+=>'	
(TIBC, twice the serum transferrin concentration, +=>	
(100 times serum iron divided by TIBC, %) were categorised into sex-specific quartiles.
3.3.4 Serum lipids 
Total serum cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides 
were measured on a Hitachi 911 Auto-analyzer, applying reagents from Boehringer, 
Mannheim. The day-to-day coefficients of variation were 1.3–1.9% for total cholesterol, 
2.4% for HDL cholesterol and 0.7–1.3% for triglycerides.  
In Paper III, we calculated non-HDL cholesterol as total cholesterol minus HDL 
cholesterol, and the total:HDL cholesterol ratio was calculated as total cholesterol 
divided by HDL cholesterol.  
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3.3.5 Age 
In all the papers, we adjusted for attained age in the analyses. In paper I, we examined 
the joint effects of blood pressure and body-mass index with the risk of deaths from 
$$	#$#		!	

years). The cut-off at 65 years corresponded closely to the median attained age of the 
participants.
3.3.6 Other possible confounders 
We stratified by sex in all analyses of the thesis, except the analysis of interaction with 
blood pressure, body-mass index and age in paper I.  
Information on participants with previous myocardial infarction and stroke was 
self-reported and collected from questionnaire I, and these participants were excluded 
from the analyses in all three papers. 
Information on prevalent diabetes mellitus was recorded as ‘yes’ or ‘no’ in 
questionnaire 1, and was adjusted for in paper I and II.  
We had information on participants with current or former use of blood pressure 
medication, and this information was included in the online-only analyses in paper I.  
In an attempt to adjust for seasonal variation in blood pressure (80), we adjusted 
for month of clinical examination in paper I. 
From questionnaire 2 we had information on smoking habits, which were 
categorised as current, former, never or unknown, and adjusted for in paper I and II.  
 Time since last meal was recorded to the nearest hour, and was adjusted for in 
paper II.
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3.3.7 End points 
In this thesis, the primary end point was deaths caused by ischaemic heart disease (ICD 
9: 410 – 414; ICD 10: I 20 – I 25) until the end of follow-up, that was 31 December 
2004 in paper I, and 31 December 2006 in paper II and paper III. 
3.4 Statistical analyses 
All statistical analyses were conducted using Stata software, release 11.0 (paper I) or 
release 11.1 (paper II and III) for Windows (Stata Corp., College Station, Texas). 
3.4.1 Cox regression 
The main method of statistical analyses was the Cox Proportional hazards model (81), 
with adjustment for potential confounding factors.  
In the analyses of blood pressure and ischaemic heart disease mortality (paper I), 
we calculated hazard ratios as the rate of death among participants within a given blood 
pressure category as compared with the rate of death in the reference category, i.e. 120-
129 mmHg for systolic and 80-84 mmHg for diastolic blood pressure. In stratified 
analyses by body-mass index, the blood pressure reference categories (120-139 mmHg 
and 80-89 mmHg, respectively) combined with body-mass index < 25 kg/m2 were used 
as the reference. These reference categories were chosen as the optimal values of blood 
pressure and body-mass index. We examined the joint effects of blood pressure and 
body-mass index in relation to deaths from ischaemic heart disease within two groups 
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		!	
). We used sub-analyses, according to the 
method of Fine and Gray (82), to test whether deaths from causes other than ischaemic 
heart disease could have competed with the observed associations with ischaemic heart 
disease mortality. 
In the analyses of iron status and ischaemic heart disease mortality (paper II), we
calculated hazard ratios as the rate of death among participants within a given iron 
status quartile as compared with the rate of death in the reference quartile, i.e. the 
reference value was the lowest quartile for serum iron and transferrin saturation and the 
highest quartile for total iron binding capacity. We first conducted analyses with 
adjustment for attained age, and with subsequent adjustment for other cardiovascular 
risk factors. 
3.4.2 Proportional hazards assumption 
We tested the proportional hazards assumption by comparing -ln-ln survival curves and 
by performing tests on Schoenfeld residuals from the Cox regression for each of the 
predictors in the analyses. If a variable did not satisfy the proportional hazards 
assumption this variable was defined as a time-dependent variable in the regression 
analysis whenever relevant.
3.4.3 Test for interaction 
In paper I, we tested for interaction effects between blood pressure and body-mass index
using likelihood ratio tests from the Cox regression analysis. To test whether the 
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interaction effect could differ by age we performed a three-way interaction test that 
included age, blood pressure, and body-mass index. 
3.4.4 Time-varying analyses 
In paper II, we explored whether the associations of iron status with ischaemic heart 
disease mortality varied during the follow-up period. This was done by calculating the 
scaled Schoenfeld residual from the Cox regression of a 1 standard deviation difference 
in transferrin saturation, serum iron and total iron binding capacity, and by constructing 
Lowess graphs of the hazard ratio by follow-up time (83). The purpose of this procedure 
was to assess whether prevalent, unknown disease related to iron status could have 
influenced the main results.  
3.4.5 Informativeness 
In the analyses of informativeness of different blood pressure, obesity and lipid indices 
in relation to ischaemic heart disease mortality (paper III), we used the method 
described by Peto et al. (84). Briefly, informativeness was calculated as the difference in 
twice the log-likelihood between a Cox proportional hazard model both adjusted for 
attained age and for blood pressure, obesity and serum lipid indices, and a model that 
only adjusted for attained age. The difference between these log-likelihoods follows a 
chi-square-distribution, and the greater the difference, the more “informative” that index 
is. In the analyses of waist-to-hip ratio adjusted for body-mass index, we included both 
variables simultaneously and compared with a model only adjusted for attained age. 
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In addition, we analysed the area under the receiver operating curves (AUC), 
pseudo R2-values from logistic regression models, estimated hazard ratios associated 
with one standard deviation increase, net reclassification improvement using a 10 % 
cut-off and integrated discrimination improvement for all predictors adjusted for 
attained age. The purpose was to provide estimates that were comparable to those of 
other studies. 
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4 Results 
4.1 Mortality from ischaemic heart disease: age-specific effects of 
blood pressure stratified by body-mass index: the HUNT cohort 
study in Norway 
We examined whether the association of blood pressure with ischaemic heart disease 
(IHD) mortality was modified by age among 34 633 men and 36 749 women with no 
history of myocardial infarction or stroke at baseline. We also examined whether the 
age-specific effects of systolic and diastolic blood pressure with IHD mortality could be 
modified by body-mass index (BMI).  
 With increasing systolic blood pressure there was a monotonic increase in the 
mortality rate for both men and women, but there was a decline in the strength of the 
association with increasing age (p for interaction < 0.01). In men younger than 65 years, 
the relative risk of IHD mortality per 20 mmHg higher systolic pressure was 1.5 (95% 
CI: 1.4–1.7), and in men 65 years and older, the corresponding association was 1.2 
(95% CI: 1.2–1.3). For women, the respective relative risks were also 1.5 (95% CI: 1.3–
1.8) and 1.2 (95% CI: 1.2–1.3). Similar patterns were observed for diastolic blood 
pressure, and the strength of the association declined with increasing age (p for 
interaction < 0.01).  
In people younger than 65 years there was a stronger risk increase with 
increasing systolic pressure among lean people (BMI < 25) compared to people with 
higher BMI (p for interaction < 0.01). Compared to the reference (systolic pressure 
120–139 mmHg and BMI < 25), the relative risk associated with systolic pressure of 
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 160 mmHg in the lean (BMI < 25) group was 5.8 (95% CI: 3.8–8.7), as compared to 
2.4 (95% CI: 1.6–3.5) in overweight (BMI 25–29) and 1.6 (95% CI: 0.9–2.8) in obese 
(BMI 
 30) people.  
?$	!
 65 years), the results displayed a similar, but substantially 
weaker pattern (p for interaction = 0.06). Thus, compared to the reference, the relative 
Y	#$'	
 160 mmHg was 2.1 (95% CI: 1.8–2.4) in 
the lean, 1.7 (95% CI: 1.5–1.9) in the overweight, and 1.8 (95% CI: 1.4–2.3) in the 
obese group. 
The stratified analyses for diastolic pressure and BMI displayed patterns that were 
weaker, but similar to the results for systolic pressure. However, in the combined 
analyses of diastolic pressure and BMI, the interaction tests indicated different patterns
than for systolic pressure. Although the interaction test was statistically significant (p
for interaction, 0.042) for diastolic pressure and BMI in people younger than 65 years, 
there was stronger evidence for an interaction between diastolic blood pressure and BMI 
in relation to deaths from ischaemic heart disease (p for interaction < 0.01) in older 
people !
 65 years).
4.2 Mortality from ischaemic heart disease: sex-specific effects of 
transferrin saturation, serum iron and total iron binding capacity. 
The HUNT Study. 
We assessed sex-specific associations of iron status with ischaemic heart disease (IHD) 
mortality, and explored whether the strength of the associations changed during follow-
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up in 28 154 men and 32 644 women without known myocardial infarction or stroke at 
baseline.  
There was a gradual increase in risk of death from IHD with decreasing level of 
transferrin saturation, with similar associations in men and women. For women in the 
lowest quartile of transferrin saturation, the hazard ratio of death from IHD was 1.4
(95% CI: 1.0–1.9) compared to women in the highest quartile (reference), and in men, 
the corresponding hazard ratio was 1.3 (95% CI: 1.0–1.6). The difference between men 
and women was not statistically significant (p for interaction = 0.87). The association of 
low iron status with ischaemic heart disease mortality was much stronger in the early 
than later stage of the follow-up period. Thus, in both genders there was a monotonic 
reduction in the hazard ratios with increasing follow-up time associated with one 
standard deviation lower transferrin saturation. In men, the hazard ratio associated with 
one standard deviation decrease in transferrin saturation was about 2.5 during the early 
stage, but decreased to about 1.5 towards the end of follow-up. There was a similar 
corresponding reduction among women, from about 2.0 to about 1.0. For both genders, 
the test of proportional hazards assumption during follow-up was p < 0.01 in men and p 
= 0.29 in women. 
Among men, but not in women, the risk of death from IHD increased with 
decreasing level of serum iron. The hazard ratio among men in the lowest compared to 
the highest quartile was 1.5 (95% CI: 1.1–1.9), and in women, the corresponding 
association was 1.1 (95% CI: 0.8–1.4). The difference between men and women was not 
statistically significant (p for interaction = 0.40). There was a reduction in the strength 
of the hazard ratios related to serum iron during follow-up. In men, the hazard ratio 
associated with one standard deviation decrease in serum iron was about 3.0 during the 
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early stage of follow-up, with a decrease to about 1.8 towards the end, and a similar 
reduction was observed for women (from 2.0 to 1.3). The proportional hazards 
assumption during follow-up was p < 0.01 in men and p = 0.84 in women. 
For total iron binding capacity (TIBC), risk of death from IHD increased with 
increasing TIBC in women, but not for men. For women in the highest compared to the 
lowest quartile (reference) of TIBC, the hazard ratio was 1.5 (95% CI: 1.1–2.0), and the 
corresponding association was 0.9 (95% CI: 0.8–1.2) for men. The gender difference 
was statistically significant (p for interaction < 0.01). For TIBC, there was a less 
consistent reduction in the hazard ratios over the follow-up period in both men and 
women. In men, the hazard ratio associated with one standard deviation increase in 
TIBC was about 2.3 in the beginning of follow-up, which decreased to about 1.5 at the 
end of the follow-up period, with a corresponding reduction from 2.2 to 1.4 among 
women. In the analysis of TIBC, the test of proportional hazards assumption during the 
follow-up period was p = 0.08 in men and p < 0.01 in women. 
It is noteworthy that the crude analyses, only adjusting for attained age, yielded 
results that were essentially identical to the results obtained after multivariable 
adjustments.
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4.3 Informativeness of indices of blood pressure, obesity and serum 
lipids in relation to ischaemic heart disease mortality: the HUNT-
II study. 
We assessed the informativeness of various indices of blood pressure, obesity and 
serum lipids in relation to ischaemic heart disease (IHD) mortality in 28 158 men and 
32 573 women without known myocardial infarction or stroke at baseline. 
The informativeness of blood pressure indices related to IHD mortality differed 
between men and women. In men, systolic blood pressure was the most informative 
index (Z21=16.8), followed by mid blood pressure (Z21=16.3), whereas in women, pulse 
pressure was the most informative index (Z21=8.8). Mid blood pressure, diastolic blood 
pressure and mean arterial pressure were the least informative indices in women.
 The informativeness of expressions of obesity and serum lipids displayed similar 
results for men and women. The waist-to-hip ratio (WHR) adjusted for body-mass index
was the most informative index !Z22=13.6 	Z22=18.2 for men and women, 
respectively) whereas WHR was slightly less informative !Z21=9.7 	Z21=17.2 for men 
and women, respectively). However, both these indices were more informative than the 
waist-to-height ratio. Although the informativeness of waist circumference alone was 
lower than using combinations of waist and hip, or waist and height measurements, the 
informativeness of waist circumference alone was nonetheless higher than that of body-
	\!Z21=0.1 	Z21=0.2 for BMI in men and women, respectively) in these 
data. 
In relation to serum lipids, the ratio of total cholesterol to high-density 
lipoprotein (HDL) $#"!Z21=35.2 	Z21=28.3 for men 
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and women, respectively) than any of the other lipids in relation to IHD mortality. 
#"	$#		'\!Z21=6.8 	Z21=24.7
for men and women, respectively), with substantially higher informativeness among 
women than men. 
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5 Discussion 
In our studies, we have used epidemiological methods to investigate mortality from 
ischaemic heart disease. Mainly, we have used survival analysis (Cox regression) in 
prospective cohorts from the HUNT studies and examined associations of non-invasive 
measurements (paper I and III), anthropometric measures (paper I and III), and 
biomarkers (paper II and III). Our principal findings were: 
 The positive association of blood pressure with risk of death from ischaemic 
heart disease was modified by body-mass index in middle age, and was much 
stronger in lean than in overweight and obese people. 
 Low iron status was associated with increased risk of death from ischaemic heart 
disease, and the associations of iron status were much stronger in the early stage 
of follow-up than in later stages of follow-up.  
 Among the indices of blood pressure, obesity and serum lipids that we assessed, 
the most informative indices related to risk of death from ischaemic heart 
disease were systolic blood pressure in men and pulse pressure in women, waist-
to-hip ratio adjusted for body-mass index both in men and women, and the ratio 
of total cholesterol to high-density lipoprotein (HDL) cholesterol for both men 
and women. Serum triglycerides also yielded high informativeness in women, 
but not in men. 
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5.1 Precision 
Could chance be a plausible explanation for our results? Chance is often equated to 
random error, and precision is the opposite of random error. A major determinant of 
precision in cohort studies is the study size (85); thus, a large study will typically yield 
more precise estimates than a smaller study. We assessed precision using statistical 
tests, and indicated the precision of the estimates by p-values or confidence intervals. 
The p-value represents the probability that the outcome of the test statistic is at least as 
extreme as the one that was actually observed, given that the null hypothesis is true. On 
the other hand, a 95 % confidence interval represents the interval in which we are 95 % 
certain that the true point estimate is, given the absence of bias and confounding. 
Usually, it is preferable to use the confidence interval, since it expresses information on 
both precision and the strength of the association. 
 In our studies we had approximately 30 000 participants of each sex. This gives 
us precise results with narrow confidence intervals in the main analyses. In sub-group 
analyses, however, the precision will be reduced. For example, in the analyses of blood 
pressure and body-mass index in paper I, the category “obese” had about 7 000 people, 
which yielded wider confidence intervals. In paper II, on the other hand, the participants 
were divided evenly into sex-specific quartiles of transferrin saturation, serum iron and 
total iron binding capacity. This resulted in more cases for each stratum, making the 
confidence intervals narrower. 
 Although the study population is large, it is a sample of an even larger
population, both geographically and  taking into account different time periods. Also, 
the proportion of participants who end up as cases is relevant in this regard. The high 
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attendance to the HUNT studies reduces the sampling variation, therefore reducing the 
likelihood that chance plays an important role in explaining our results. The large 
number of deaths from ischaemic heart disease adds to this, making chance an unlikely 
explanation for our findings. 
5.2 Validity 
Is the observed association between exposure and disease true? The objective of an 
epidemiologic study is to obtain estimates that are both valid and generalizable to 
relevant target populations (86). Validity is the opposite of systematic error, or bias. 
However, that a study provides valid results does not necessarily mean that the results 
represent causal associations between a given factor and a given outcome. Causality is a 
matter of inference, but high validity is necessary for making causal inferences.  
Validity is also classified as internal or external. In the assessment of internal 
validity of a certain study, one needs to evaluate the potential for confounding, selection 
bias and information bias. External validity, however, refers to whether the results of 
the study can be generalized to other populations or groups of people.  
5.2.1 Confounding 
The association of an exposure with an outcome may be confounded by other factors 
(86). Thus, the exposure may be associated with a third factor, which also has an effect 
on the outcome. However, a factor that is on the causal pathway from exposure to 
outcome should not be treated as a confounder. Therefore, the assessment of potential 
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confounding should be done with care, and preferably on the basis of previous 
knowledge and using careful reasoning, rather than basing the assessment of 
confounding on p-values linked to the co-variates entered into the analyses.  
There are usually two ways of dealing with confounders; one is to use 
stratification and the other is to adjust for potential confounding in regression analyses. 
In our papers, we have used both strategies. We have mostly done separate analyses in 
men and women, and thus stratified by sex. We have also used regression analysis to 
adjust for sex in the analyses of blood pressure, body-mass index and age in paper I. In 
relation to age, we adjusted for attained age in all analyses and stratified by the median 
attained age in paper I.
Furthermore, we have used regression analysis to adjust for diabetes mellitus 
(paper I and II), smoking status (paper I and II), body-mass index (paper I), systolic 
blood pressure (paper II), total:HDL cholesterol ratio (paper II), waist-to-hip ratio 
(paper II), and time since last meal (paper II).
 Factors we had information on, but were not used or considered as confounders 
in the main analyses, included the use of blood pressure medication (confounding by 
indication), alcohol use (too many missing), and exercise frequency (too many missing). 
5.2.2 Selection bias 
Whenever the relation between exposure and disease in a population study differs 
between participants and non-participants in the population, a selection bias may 
explain the results (86). Unlike confounders, it is not possible to adjust for the effects of 
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a bias; bias needs to be dealt with in the planning of a study. However, it is possible to 
investigate whether those who participate differ from those who do not.  
 In our studies, the population of an entire county older than 20 years of age was 
eligible to participate. If attendance is high, any effect of selection bias will be reduced. 
However, if the attendance is not that high, the possibility for selective non-
participation could disturb the estimated results. In HUNT 1, 11.9 % of those who were 
invited, did not participate, and in HUNT 2, the corresponding proportion was 28.8 % 
(75). A non-responder study was conducted after HUNT 2, and the major reason for not 
participating was lack of time in younger people and immobilising disease in the elderly 
(87). The non-responders differed in that they reported a higher level of smoking, which 
is an important factor that could have influenced our results. 
 We made certain restrictions of participants in the analyses, and possibly, some 
of these restrictions could have introduced a selection bias. In order to investigate a 
healthy population, we excluded participants with a history of heart disease or stroke at 
baseline. We performed sensitivity analyses where these participants were included in 
the analyses, after which the associations became weaker (data not shown). However, 
the directions and patterns of the point estimates were essentially the same. Thus, it 
appears that the sub-group with prevalent cardiovascular disease has random 
characteristics that would attenuate the estimates of effect towards the null value. 
5.2.3 Information bias 
Information bias is a systematic inaccuracy or error in the collected information. It is 
called misclassification bias if the information is on a categorical scale (88). This bias 
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can be subdivided into differential and non-differential misclassification. A differential 
misclassification is when the errors of one variable depend on the actual values of other 
variables. As a result, the point estimates could go in either direction. A non-differential 
misclassification is unrelated to the actual values of other variables, and will usually 
attenuate the estimated associations towards the null value.
 In our studies, many variables may be prone to information bias. The use of 
standard blood pressure cuffs in paper I could lead to overestimation of blood pressure 
in overweight and obese people, or among people with large upper arms. This source of 
differential misclassification could cause people with large upper arms to be incorrectly 
classified with hypertension. Thus, the estimated association of blood pressure with 
IHD mortality may be weaker than the true association in these people. 
There may be information bias in self-reported data, such as time since last meal, 
smoking status and prevalence of diabetes mellitus. There may also be misclassification 
in causes of death. Furthermore, the measured values of weight, height, waist and hip 
circumference, serum iron, total iron-binding capacity, total and HDL cholesterol and 
triglycerides may suffer from random measurement error which may attenuate the 
estimates towards the null value.
 To avoid differential misclassification, we excluded participants with previous 
heart disease or stroke from all analyses. In these individuals, the medical attention or 
treatment may have altered both self-reported and measured data.
 Prospective cohort studies are less prone to information bias than other studies 
(e.g. case-control studies). However, during long follow-up periods, measured values at 
baseline may change. For instance, people with detected hypertension at HUNT 1 were 
referred to their primary physician (78). These may have started anti-hypertensive 
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medication that could have resulted in underestimation of the risk of high blood 
pressure.  
Blood pressure values may vary over time, and compared to baseline levels, 
blood pressure during follow-up is not likely to be constant. Therefore, the lack of 
longitudinal measurements during the follow-up period is a weakness of our study. 
Most likely, this weakness has caused a “dilution” effect, meaning that the estimated 
associations are underestimates of the true associations related to blood pressure.  It has 
been suggested that this regression dilution bias (89) could be corrected by using 
repeated measurements in a reasonably representative sample of participants in the 
study (7).  
5.2.4 Generalizability 
Where and to whom do our results apply? Some believe that a representative study 
should sample the study population to closely resemble the population at large, while 
others believe a homogenous study population is necessary to identify more valid causal 
relations (86). In our studies we have both a representative sample by age and sex, and a 
homogenous sample by ethnicity and geographical location. In other words, our sample 
is representative for the Nord-Trøndelag adult population, and may therefore allow the 
assessment of risk factors in relation to ischaemic heart disease mortality. The external
validity of our results may be limited if these associations differ between Nord-
Trøndelag and other populations. 
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5.3 Appraisal of the principal findings 
5.3.1 The age-specific associations of blood pressure and body-mass index 
with ischaemic heart disease (IHD) mortality 
We found a relatively stronger, positive association of blood pressure with IHD 
mortality among younger, lean individuals, thus giving evidence for effect modification 
by age and by body-mass index (BMI).  
The effect modification by age, where the association of blood pressure with 
IHD mortality is stronger at younger ages, is consistent with previous findings (7). The 
effect modification by BMI, where the association of blood pressure with IHD mortality 
is stronger in lean than overweight people, is consistent with some studies (28-34), but 
not with others (35-39). To our knowledge, the combined effect modification of age and 
BMI has only been assessed and reported in one previous study (34), and in that study, 
there was no significant difference between age groups. However, it was reported that 
low BMI was more strongly associated with increased risk of coronary heart disease in 
men both at young and older ages, but in women, there were no similar findings. 
Between studies, it has not been consistently shown that lean hypertensive 
people are at greater risk of cardiovascular disease than obese hypertensive people.
Lean hypertensive people tend to be at greater risk in studies where the main outcome is 
mortality (28-34), whereas obese hypertensive people appear to be at greater risk in 
studies where the main outcome is morbidity (35-39). We only studied mortality as an 
outcome, and our findings correspond to those of previous studies using mortality.
Other possibilities for the different results between studies include heterogeneity 
between populations and different analytical strategies (33,36). It is also possible that 
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the relation of blood pressure and BMI with cardiovascular disease may truly differ 
between populations. 
Hypertension in lean and young people may be a sign of a relatively more life 
threatening type of hypertension that may cause premature death. A relatively strong 
association of hypertension with death from IHD in lean people may reflect genetic 
susceptibility (90,91), increased peripheral resistance (92) or underlying biological 
mechanisms that may differ from other mechanisms of hypertension (93,94). In young 
people, the relatively stronger association of hypertension may further reflect a more 
severe type of hypertension than is typically observed among elderly people. As a 
consequence, the relatively weaker association of hypertension with deaths from IHD at 
older ages may reflect selective survival of individuals who are less vulnerable to high 
blood pressure.  
Smokers usually have lower BMI than non-smokers (95), and this could have 
influenced our results. However, after adjustment for smoking, we found that the results 
remained essentially the same. This is also in accordance with the findings of others
(28,30,33).  
As mentioned in section 5.2.3, the use of standard cuff size in people with wide 
arm circumference could lead to incorrectly elevated blood pressures (96). However, 
previous studies that were able to account for this possibility, did not provide evidence 
that the results could be attributed to inappropriate cuff size (29,30,33). 
The age-related differences in relative risks of death from IHD could be 
attributed to cohort effects. Thus, different birth cohorts could have experienced 
different exposures, especially during childhood and adolescence. It is possible that 
such potential differences could be relevant for long term effects of blood pressure on
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cardiovascular health (97,98). It also seems possible that secular trends in nutrition from 
a relatively sparse diet at a young age, to a richer diet later in life, could be of 
importance for the interaction between blood pressure and body-mass index (99). 
5.3.2 The sex-specific association of iron status with ischaemic heart disease 
mortality (IHD) mortality 
We found a linear, negative association of iron status with IHD mortality, but the 
associations were stronger during the early phase of follow-up than in the later phase. 
This may suggest that low iron status could be a late sign of IHD pathology or that 
unknown prevalent disease at baseline could influence the associations.  
The association of low transferrin saturation with higher cardiovascular 
mortality has previously been shown in one study (61), but not specifically for IHD 
mortality as reported in paper II. The corresponding association of low serum iron, as 
we found among men, has been reported by others (62,100). In two other studies, low 
serum iron was associated with higher risk in women, but not in men (50,53). It has also 
been suggested that high levels of serum iron, in both men and women, may be
associated with the risk of dying from myocardial infarction (54). Our finding that high 
levels of total iron binding capacity (TIBC) may be associated with increased risk of 
death from IHD differs from the results of others; previously, either opposite (52,55) or 
no associations (50-52,58) have been reported. 
Low iron status could be a late sign in the pathogenesis of IHD, and an 
inflammatory response has, for example, been suggested as one possible explanation 
(101), and reverse causality may be another possibility. Thus, unknown but underlying 
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disease could influence iron status and the association with IHD mortality. For example, 
unknown cardiovascular disease, cancer (102), chronic infections (102), rheumatic 
diseases (103), or chronic kidney disease (104) could cause low iron status and thereby 
influence the association with IHD mortality. Since we found stronger associations 
during the early phase of follow-up, both possibilities may be supported by our findings.  
Our results may also reflect the association of iron with haem (105), since 
anaemia could increase the risk of cardiovascular morbidity and mortality (106). 
Specifically, it has been shown that anaemia is associated with increased risk of 
cardiovascular events in patients with hypertension (107), atrial fibrillation (108), 
coronary heart disease (109-112), and chronic heart failure (113,114).  
5.3.3 The sex-specific informativeness of blood pressure, obesity and serum 
lipid indices with ischaemic heart disease (IHD) mortality 
Our study of informativeness suggests that different indices of known risk factors may 
differ in their usefulness in relation to estimates of IHD mortality. In relation to blood 
pressure, we found that systolic blood pressure in men and pulse pressure in women 
may be more informative than other indices. In relation to obesity, waist-to-hip ratio 
adjusted for body-mass index (BMI) was more informative than other indices of body 
mass in both sexes. For serum lipids, we found that the ratio of total cholesterol to high-
density lipoprotein (HDL) cholesterol was more informative than other indices for both 
men and women.  
Our results related to obesity and serum lipids are consistent with findings of 
previous studies (23,71). It has been suggested that waist-to-height ratio may be the 
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most informative obesity index (115), but we found it to be less informative than waist-
to-hip ratio adjusted for BMI. Our results related to blood pressure, suggesting that 
systolic blood pressure is the most informative in men and pulse pressure in women, 
deviate from the findings of others. Thus, mid blood pressure has been suggested to be 
the most informative index (7), and we also found that index to be relatively informative 
in men, but not in women. Also, others have found that pulse pressure may be
informative both in middle and old age, with no clear sex difference, which corresponds 
to our findings (116). 
 The reason for a sex difference in blood pressure indices is not clear, but others 
have suggested that pulse pressure may be particularly informative in old age (116-118). 
Since there is a substantial age difference by sex in being diagnosed with ischaemic 
heart disease (119), the age difference may be important for the difference in 
informativeness related to pulse pressure. It has also been suggested that men and 
women have different patterns of arterial aging (120), and this could be of important for 
our findings. 
 We did not find mid blood pressure to be as informative as reported in other 
studies (7). This could be due to the low informativeness of diastolic blood pressure in 
our study, since diastolic blood pressure is a component of mid blood pressure.
The waist-to-hip ratio adjusted for BMI combines information on abdominal 
obesity and general obesity, which may explain the high informativeness related to this 
obesity index. This combined index has also been suggested to improve informativeness 
in relation to all-cause mortality, especially in people with low BMI (23).  
The ratio of total cholesterol and high-density lipoprotein (HDL) cholesterol was 
the most informative expression of serum lipids related to IHD mortality in both men 
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and women. The reason for the high informativeness may be the combination of two 
relatively informative indices into one.  
5.4 Conclusions and implications 
 We found that the association of blood pressure with ischaemic heart disease 
mortality was modified by age and body-mass index. Thus, lean and relatively 
young individuals with hypertension were at increased risk of death from 
ischaemic heart disease. These findings are in accordance with similar studies of 
cardiovascular disease mortality, but not with studies of morbidity. This 
discrepancy is worthy of further investigations, and hopefully, other large, 
prospective studies that can use both morbidity and mortality end-points could 
elucidate this further. Also, the relative differences in the association of blood 
pressure between lean and overweight/obese people could imply that the 
pathophysiology between these groups may differ both in relation to 
hypertension and ischaemic heart disease.  To investigate this difference further, 
it might be useful to apply the approaches of some relatively small cross-
sectional studies in larger prospective studies, in particularly, by including 
metabolic, neuroendocrine and cardiovascular characteristics in the analyses
(121), and by evaluating sympathetic nervous system activity (93,94). 
Furthermore, our results may support that young and lean hypertensive people 
could benefit from closer monitoring by their physicians.
 Our results indicate that low iron status is associated with increased risk of death 
from ischaemic heart disease. Specifically, we found this for transferrin 
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saturation, serum iron and total iron binding capacity. This is in accordance with 
some studies, but not with others. It is interesting to note that this association 
was much stronger during the early phase of the follow-up period. This could 
imply that low iron status is a late marker in the pathogenesis of ischaemic heart 
disease or alternatively, that unknown but underlying disease could have 
influenced iron status. These findings warrant confirmation by other studies, and 
it could be useful to investigate this issue in studies with information on other 
iron markers and related biomarkers (e.g. ferritin, transferrin receptor, 
haemoglobin, and C-reactive protein). Furthermore, our results may support that 
low iron status should stimulate physicians to search for underlying 
mechanisms.
 There are many indices of blood pressure, obesity and serum lipids, and our 
results suggest that systolic blood pressure in men, pulse pressure in women, 
waist to hip ratio adjusted for body-mass index in men and women, and 
total:HDL cholesterol ratio in men and women are the most informative in 
relation to assessing ischaemic heart disease mortality. Other studies support our 
findings for obesity and serum lipids, but for blood pressure, the mid blood 
pressure was the most informative in a large meta-analysis (7). The most 
informative index should be considered by researchers when choosing which 
index to study or to adjust for. Also, the approach of determining 
informativeness could be investigated for other indices and other diseases.
Furthermore, our results suggest that it may be useful for physicians to use more 
informative measurements in the clinical management of patients.
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Abstract The informativeness of blood pressure, obesity
and serum lipids associated with cardiovascular events may
depend on how the indices are expressed, and mid blood
pressure, waist-to-hip ratio adjusted for body-mass index
(BMI) and the ratio of total to HDL cholesterol may be more
informative than other expressions. Our aimwas to study the
informativeness of indices of blood pressure, obesity and
serum lipids associated with ischaemic heart disease mor-
tality in a large, homogeneous population. Blood pressure,
weight, height, waist and hip circumference, total and HDL
cholesterol, and triglycerides were measured at baseline
(1995–1997) in 28,158 men and 32,573 women. Informa-
tion on deaths from ischaemic heart disease (IHD) was
obtained from the Causes of Death Registry in Norway from
baseline until the end of 2007. Informativeness was analysed
using the difference in twice the log-likelihood of a Cox
model with and without each index. During 11 years of
follow-up, 597 men and 418 women had died from IHD.
Systolic blood pressure in men and pulse pressure in women
were the most informative predictors of blood pressure, and
waist-to-hip ratio adjusted for BMI was the most informa-
tive expression of obesity in both men and women. Among
serum lipids, the most informative predictor was the ratio of
total cholesterol to HDL cholesterol. Using more informa-
tive expressions of conventional risk factors for ischemic
heart disease may improve both the validity and precision of
estimates of risk, and may be useful both clinically and for
preventive purposes.
Keywords Ischaemic heart disease  Blood pressure 
Obesity  Lipids  Risk  Informativeness
Introduction
Blood pressure, obesity and serum lipids are associated
with the risk of ischaemic heart disease, but the preferred
expression of these indices appears to change over time,
maybe reﬂecting their evolving conceived importance [1–
3]. The informativeness of an index is meant to capture
how well it predicts the outcome. In relation to blood
pressure, for example, mid blood pressure has been sug-
gested to be the most informative index in relation to
ischaemic heart disease mortality [4]. Similarly, among
obesity indices, the ratio of waist-to-hip circumference,
adjusted for body-mass index, may be the most informative
predictor [5], but the ratio of waist-to-height has also been
suggested [6]. Among serum lipids, the ratio of total cho-
lesterol to HDL cholesterol may be the most informative
predictor for ischaemic heart disease mortality [7].
The ranking of indicators is based on the results of meta-
analyses of studies consisting of heterogeneous populations
[4, 5, 7]. However, we have assessed informativeness of
various indices of blood pressure, obesity and serum lipids
in relation to ischaemic heart disease mortality using data
from a large, homogeneous cohort, with separate analyses
of men and women.
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Methods
Study population
The adult population 20 years of age and older in Nord
Trøndelag County in Norway was invited to participate in a
health survey (the HUNT II Study) from August 1995 to
June 1997. Brieﬂy, 92,936 individuals were eligible to
participate in the study, and 64,939 (69.9%) accepted the
invitation, ﬁlled in a questionnaire that was included with
the invitation letter, and attended a clinical examination
conducted by trained nurses. Among other factors the
examination included standardised measurements of blood
pressure, body weight, body height, waist and hip cir-
cumference, and a non-fasting blood sample with sub-
sequent measurements of total serum cholesterol, HDL
cholesterol and triglycerides. The study has been described
in more detail elsewhere [8].
For the present study, we excluded 769 participants
with missing information on waist or hip circumference
and 132 participants with missing information on total
cholesterol, HDL cholesterol or triglycerides, as well as
63 participants with missing information on blood pres-
sure and 194 participants with missing information on
weight and height. We also excluded 3,050 participants
with a history of myocardial infarction or stroke at
baseline. Thus, 60,731 participants (28,158 men and
32,573 women) were included in the main sex-speciﬁc
analyses of informativeness of predictors of ischaemic
heart disease mortality.
The mortality follow-up of the HUNT cohort was
approved by the regional committee for ethics in medical
research, by the national Directorate of Health, and by the
Norwegian Data Inspectorate.
Blood pressure, obesity and lipid indices
Systolic and diastolic blood pressure were measured using
a Dinamap 845XT (Critikon) based on oscillometry, and
the average of the second and third measurements was
used. From these indices we calculated mean arterial
pressure as the sum of systolic blood pressure and twice the
diastolic blood pressure divided by three. Mid blood
pressure was calculated as the average of systolic and
diastolic blood pressure. Pulse pressure was calculated as
the difference between systolic and diastolic blood pres-
sure. Pulse pressure 9 Mean arterial pressure is the prod-
uct of these indices.
At the clinical examination, height was measured to the
nearest centimetre; weight to the nearest half kilogram; and
waist and hip circumferences to the nearest centimetre.
From these indices we further calculated waist-to-hip ratio,
waist-to-height ratio and body-mass index (kg/m2).
A blood sample (non-fasting) was drawn from all the
participants, centrifuged at the study site, and sent in a
cooler to the laboratory. Total serum cholesterol, HDL
cholesterol, and triglycerides were measured on a Hitachi
911 Auto-analyzer, applying reagents from Boehringer
Mannheim. The day-to-day coefﬁcients of variation were
1.3–1.9% for total cholesterol, 2.4% for HDL cholesterol
and 0.7–1.3% for triglycerides.
We calculated non-HDL cholesterol as total cholesterol
minus HDL cholesterol, and the total:HDL cholesterol ratio
was calculated as total cholesterol divided by HDL
cholesterol.
End points
The mandatory reporting of deaths by physicians and public
health ofﬁcers to the national Cause of Death Registry in
Norway constitutes the basis for the coding of underlying
causes of death. Mortality follow-up to the Cause of Death
Registry is virtually complete. In this study, the primary end
point was deaths caused by ischaemic heart disease (ICD 9:
410–414; ICD 10: I 20–I 25).
Statistical analyses
Follow-up time (person-time) was calculated from the
baseline date of participating in the HUNT Study until date
of death, or until the end of follow-up, 31 December 2006,
whichever occurred ﬁrst.
We analysed informativeness of different blood pressure,
obesity and lipid indices in relation to ischaemic heart dis-
ease mortality, according to the method described by Peto
et al. [9]. Brieﬂy, informativeness was calculated as the
difference in twice the log-likelihood between a Cox pro-
portional hazard model both adjusted for attained age and
each respective blood pressure, obesity or serum lipid index,
and a model that only adjusted for attained age. The differ-
ence between these log-likelihoods follows a chi-square-
distribution, and the greater the difference, the more
‘‘informative’’ that index is. In the analyses of waist-to-hip
ratio adjusted for BMI, we included both variables simulta-
neously and compared with a model only adjusted for
attained age.
We tested the proportional hazards assumption by com-
paring -ln-ln survival curves and by performing tests on
Schoenfeld residuals for each of the predictors of the study. If
a predictor did not satisfy the proportional hazards assump-
tion this was deﬁned as time-dependent whenever relevant.
In addition, we analysed the area under the receiver
operating curves (AUC), pseudo R2 values from logistic
regression models, estimated hazard ratios associated with
one standard deviation increase, net reclassiﬁcation
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improvement using a 10% cut-off and integrated discrim-
ination improvement for all predictors adjusted for attained
age, and present the results as a web-only appendix for the
purpose of comparison with other studies.
All statistical analyses were conducted using Stata
software, release 11.1 for Windows (Stata Corp., College
Station, Texas).
Results
During 11.4 years of follow-up (over 600,000 person-
years) 1,015 men and women had died from ischaemic
heart disease (Table 1), yielding a mortality rate of 166.8
per 100,000 person-years.
The informativeness of blood pressure indices related to
ischaemic heart disease (IHD) mortality differed between
men and women (Table 2). In men systolic blood pressure
was the most informative index (v1
2 = 16.8), followed by
mid blood pressure (v1
2 = 16.3), whereas in women, pulse
pressure was the most informative index (v1
2 = 8.8). Mid
blood pressure, diastolic blood pressure and mean arterial
pressure were the least informative indices in women.
The informativeness of expressions of obesity and serum
lipids displayed similar results formen andwomen (Tables 3
and 4). Thewaist-to-hip ratio (WHR) adjusted for body-mass
index was the most informative index (v2
2 = 13.6 and
v2
2 = 18.2 for men and women, respectively) whereas WHR
was slightly less informative (v1
2 = 9.7 and v1
2 = 17.2 for
men and women, respectively) (Table 3). However, both
these indices were more informative than the waist-to-height
ratio. Although the informativeness of waist circumference
alone was lower than using combinations of waist and hip, or
waist and heightmeasurements, the informativeness of waist
circumference alone was nonetheless higher than that of
body-mass index (v1
2 = 0.1 and v1
2 = 0.2 for BMI inmen and
women, respectively) in these data.
In relation to serum lipids (Table 4), the ratio of total
cholesterol to HDL cholesterol was more informative
(v1
2 = 35.2 and v1
2 = 28.3 for men and women, respec-
tively) than any of the other lipids in relation to IHD
mortality. However, serum triglycerides showed a clear
difference by sex (v1
2 = 6.8 and v1
2 = 24.7 for men and
women, respectively), with substantially higher informa-
tiveness among women than men.
Discussion
In this prospective study of 60,731 men and women who
were free from known cardiovascular disease at baseline,
we assessed the informativeness of different indices of
blood pressure, obesity and serum lipids in relation to IHD
mortality. The most informative indices were systolic
blood pressure in men and pulse pressure in women, waist-
to-hip ratio adjusted for body-mass index both in men and
women, and the ratio of total cholesterol to HDL choles-
terol for both men and women. However, serum triglyc-
erides also yielded high informativeness in women, but not
in men.
There is evidence in the literature to support our results
related to indices of obesity and serum lipids [5, 7, 10], but
we were unable to ﬁnd results related to blood pressure that
corresponded to ours. Although it has been suggested that
the waist-to-height ratio may be an informative obesity
index [6], we found it to be less informative than the waist-
to-hip ratio adjusted for BMI. Previously, it has been
suggested that mid blood pressure may be the most infor-
mative blood pressure index [4], but in our data, this index
showed relatively high informativeness in men, but not in
women. We found that systolic pressure may be most
informative in men, and pulse pressure in women. Previ-
ously, it has been suggested that pulse pressure may be
particularly informative both in middle and old age, but
with no clear difference between men and women [11].
This cohort consists of the majority of adults in a stable,
homogeneous population in Norway. The population is
well suited for follow-up studies, partly because of excel-
lent national end-point registries, and partly because of the
unique identiﬁcation number allocated to each citizen.
The prospective study design reduces the possibility of
biased estimates of effect, and the large study size makes
Table 1 Characteristics of the study population (n = 60,731)
Men Women
Participants, n (%) 28,158 (46) 32,573 (54)
Age at baseline, years 49 (16) 50 (17)
Systolic blood pressure, mmHg 140 (19) 135 (23)
Diastolic blood pressure, mmHg 82 (12) 79 (12)
Mean arterial pressure, mmHg 101 (13) 98 (15)
Mid blood pressure, mmHg 111 (14) 107 (17)
Pulse pressure 58 (13) 57 (16)
Waist-to-hip ratio 0.90 (0.06) 0.80 (0.06)
Body-mass index, kg/m2 26 (3) 26 (5)
Waist circumference, cm 92 (9) 81 (11)
Hip circumference, cm 102 (6) 102 (9)
Weight, kg 83 (12) 70 (12)
Total:HDL-cholesterol ratio, mmol/l 5.0 (1.7) 4.2 (1.5)
Non-HDL-cholesterol, mmol/l 4.6 (1.2) 4.4 (1.4)
Total cholesterol, mmol/l 5.8 (1.2) 5.9 (1.3)
HDL-cholesterol, mmol/l 1.2 (0.3) 1.5 (0.4)
Triglycerides, mmol/l 2.0 (1.2) 1.5 (1.0)
Deaths from ischaemic heart disease, n 597 418
Continuous variables are expressed as mean (SD)
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chance an unlikely explanation of the main ﬁndings. Sep-
arate analysis of men and women is another strength of this
study. In the analyses, we used the difference in twice the
log-likelihood from a Cox regression model, instead of
using AUC and pseudo R2 from a logistic regression
model. Our approach has the beneﬁt of considering person-
time and censoring and is likely to yield more valid esti-
mates than the other methods [9].
Some limitations should, however, be considered. It has
been suggested that the informativeness of blood pressure
indices changes with age [12], and despite the large sample
size, we did not have sufﬁcient statistical power to study age-
speciﬁc informativeness of these indices in detail. Further-
more, we did not have information available on non-fatal
myocardial infarction or stroke and therefore, censoring for
these events could not be done. Another limitation is the
single measurements at one time point and no repeated
measurements. Thus, we did not have data available
that allowed adjustment for possible regression dilution
effects [4].
The reason for the difference in informativeness of
blood pressure between men and women is uncertain, but
others have suggested that pulse pressure may be particu-
larly informative in old age [11–13] and women are usually
diagnosed with ischaemic heart disease at an older age than
men [14]. It has also been suggested that men and women
have different patterns of arterial aging [15], and this could
be of important for our ﬁndings.
The relatively low informativeness of mid blood pres-
sure, that others have suggested to be highly informative in
relation to IHD mortality [4], could be due to the lack of
informativeness of diastolic blood pressure in our study,
since diastolic blood pressure is a component of mid blood
pressure.
The waist-to-hip ratio adjusted for BMI combines
information on abdominal obesity and general obesity,
Table 2 Informativeness of different blood pressure indices related to ischaemic heart disease mortality, by sex
Men v2 P Women v2 P
Systolic blood pressure 16.8 \0.001 Pulse pressure 8.8 0.003
Mid blood pressure 16.3 \0.001 Pulse pressure 9 mean arterial pressure 4.1 0.043
Pulse pressure 9 mean arterial pressure 16.2 \0.001 Systolic blood pressure 3.0 0.086
Mean arterial pressure 15.0 \0.001 Mid blood pressure 0.7 0.393
Pulse pressure 10.3 0.001 Diastolic blood pressure 0.6 0.448
Diastolic blood pressure 9.6 0.002 Mean arterial pressure 0.2 0.687
Adjusted for attained age. Sex-speciﬁc sorted by most informative as deﬁned by high value of v2
Table 3 Informativeness of different obesity indices related to ischaemic heart disease mortality, by sex
Men v2 P Women v2 P
Waist-to-hip ratio adjusted for BMI 15.4 \0.001 Waist-to-hip ratio adjusted for BMI 20.3 \0.001
Waist-to-hip ratio 12.0 \0.001 Waist-to-hip ratio 19.3 \0.001
Waist-to-height ratio 11.3 \0.001 Waist-to-height ratio 8.0 0.005
Weight 2.3 0.128 Waist circumference 5.7 0.017
Waist circumference 4.0 0.044 BMI 0.2 0.671
Hip circumference 0.3 0.610 Weight 0.1 0.763
BMI \0.1 0.808 Hip circumference \0.1 0.873
Adjusted for attained age. Sex-speciﬁc sorted by most informative as deﬁned by high value of v2
Table 4 Informativeness of different serum lipid indices related to ischaemic heart disease mortality, by sex
Men v2 P Women v2 P
Total:HDL-cholesterol ratio 35.2 \0.001 Total:HDL-cholesterol ratio 28.3 \0.001
Non-HDL cholesterol 29.8 \0.001 Triglycerides 24.7 \0.001
Total cholesterol 19.1 \0.001 HDL cholesterol 17.6 \0.001
HDL cholesterol 14.5 \0.001 Non-HDL cholesterol 14.8 \0.001
Triglycerides 6.8 0.009 Total cholesterol 6.6 0.010
Adjusted for attained age. Sex-speciﬁc sorted by most informative as deﬁned by high value of v2
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which may explain the high informativeness related to this
obesity index. This combined index has also been sug-
gested to improve informativeness in relation to all-cause
mortality, especially in people with low BMI [5].
Similarly, by combining total cholesterol and HDL
cholesterol to a ratio, this index was the most informative
expression of serum lipids related to IHD mortality in both
men and women. The superiority of combining the two
measurements into a single index may simply be due to the
individual strength of both total and HDL cholesterol.
Serum triglycerides were especially informative in women,
but not in men. The reason for the sex difference related to
triglycerides is uncertain, but an imbalance between calorie
intake, content and composition of diet, and a sedentary life
style has been suggested [16].
Conclusions
The use of the most informative indices may improve the
prediction of ischaemic heart disease mortality, and may be
useful in choosing a preferred index in cardiovascular
research. Also, our ﬁndings suggest that different indices of
blood pressure in men and women may be useful, and that
using the waist-to-hip ratio adjusted or stratiﬁed by BMI
could also improve estimates of risk.
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Webtable 1 Other methods of calculating informativeness of different blood pressure, obesity 
and serum lipid indices related to ischaemic heart disease mortality, for men
Men AUC R2 HR NRI IDI
Blood pressure 
Systolic blood pressure 0.841 0.162 1.153 0.020 0.004
Mid blood pressure 0.839 0.160 1.157 0.012 0.003
Pulse pressure × Mean arterial pressure 0.841 0.162 1.148 0.020 0.004
Mean arterial pressure 0.838 0.159 1.154 0.013 0.002
Pulse pressure 0.840 0.160 1.114 0.024 0.004
Diastolic blood pressure 0.835 0.156 1.128 0.011 <0.001
Obesity
Waist-to-hip ratio adjusted for BMI 0.838 0.158 1.202 0.015 0.002
Waist-to-hip ratio 0.838 0.157 1.149 0.006 <0.001
Waist-to-height ratio 0.838 0.158 1.149 0.017 0.002
Weight 0.834 0.154 0.935 -0.005 <0.001
Waist circumference 0.835 0.155 1.086 -0.003 -0.001
Hip circumference 0.833 0.153 0.979 0.011 0.001
Body-mass index 0.833 0.153 1.010 0.003 <0.001
Serum lipids
Total:HDL-cholesterol ratio 0.838 0.160 1.256 0.023 0.003
Non-HDL cholesterol 0.837 0.160 1.259 0.026 0.003
Total cholesterol 0.835 0.158 1.203 0.022 0.002
HDL cholesterol 0.836 0.156 0.857 0.012 0.001
Triglycerides 0.834 0.154 1.114 -0.001 <0.001
Sorted as the corresponding tables in the article. Adjusted for attained age. AUC: area under 
the curve; R2: pseudo R2 from logistic regression; HR: hazard ratio associated with 1 standard 
deviation increase; NRI: net reclassification improvement using a 10% cut-off; IDI: integrated 
discrimination improvement.
Webtable 2 Other methods of calculating informativeness of different blood pressure, obesity 
and serum lipid indices related to ischaemic heart disease mortality, for women
Women AUC R2 HR NRI IDI
Blood pressure
Pulse pressure 0.885 0.207 1.145 0.020 0.003
Pulse pressure × Mean arterial pressure 0.883 0.205 1.103 0.006 0.002
Systolic blood pressure 0.882 0.204 1.086 0.008 0.001
Mid blood pressure 0.880 0.201 1.041 0.002 <0.001
Diastolic blood pressure 0.878 0.199 0.968 <0.001 <0.001
Mean arterial pressure 0.879 0.200 1.018 <0.001 <0.001
Obesity
Waist-to-hip ratio adjusted for BMI 0.883 0.205 1.264 0.015 0.002
Waist-to-hip ratio 0.883 0.205 1.242 0.010 0.002
Waist-to-height ratio 0.882 0.203 1.158 -0.006 <0.001
Waist circumference 0.880 0.201 1.132 -0.008 <0.001
Body-mass index 0.878 0.199 1.021 -0.007 -0.001
Weight 0.878 0.199 0.985 0.002 <0.001
Hip circumference 0.878 0.199 0.992 -0.007 <0.001
Serum lipids
Total:HDL-cholesterol ratio 0.882 0.207 1.231 0.035 0.004
Triglycerides 0.882 0.206 1.222 0.020 0.003
HDL cholesterol 0.881 0.204 0.814 0.015 0.003
Non-HDL cholesterol 0.881 0.204 1.220 0.009 0.001
Total cholesterol 0.880 0.202 1.144 -0.014 <0.001
Sorted as the corresponding tables in the article. Adjusted for attained age. AUC: area under 
the curve; R2: pseudo R2 from logistic regression; HR: hazard ratio associated with 1 standard 
deviation increase; NRI: net reclassification improvement using a 10% cut-off; IDI: integrated 
discrimination improvement.
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